The New Oral Anticoagulants: Handle with Care Philip C. Comp, M.D., Ph.D. October 18, 2013.

Slides:



Advertisements
Similar presentations
Advanced Practice of Pharmacy Experience: Journal Club Mai Nguyen Mercer University COPHS Doctor of Pharmacy Candidate 2012 Preceptor: Dr. Ali Rahimi.
Advertisements

Educational Event 23rd & 24th January 2013
JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.
The Changing Landscape of Anticoagulation William D. Cahoon, Jr., PharmD, BCPS Cardiology Clinical Pharmacist VCU Health System April 12, 2012.
Update on the New Oral Anticoagulants
 Knowledge of the commonly used anticoagulant drugs is important in reducing the likelihood of patient harm associated with their administration.  Common.
Newer Anticoagulants Drug Class Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services October 16, 2013.
Spotlight Case New Oral Anticoagulants. This presentation is based on the December 2013 AHRQ WebM&M Spotlight Case –See the full article at
New Oral Anticoagulants (NOACs) Dabigatran and Rivaroxaban for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation Dr Dipti.
ORAL ANTICOAGULANTS IN THE 21 ST CENTURY: A PRACTICAL GUIDE TO USING NEWER AGENTS Katherine Vogel Anderson, Pharm.D., BCACP University of Florida Colleges.
CLINICAL CASES.
DR DIPTI CHITNAVIS HAEMATOLOGY CONSULTANT WEST SUFFOLK HOSPITAL JANUARY 2014 Update on the new oral anticoagulants; 12 months on.
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey.
NEW ORAL ANTICOAGULANTS
Preventing Anticoagulation Errors with Clinical Dashboards Dan Johnson, Pharm.D., BCPS August 3, 2011.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Cross-Canada Collaboration to Promote Evidence-Based Use of Anticoagulants CADTH SYMPOSIUM APRIL 14, 2015.
AF and NOACs An UPDATE JULY 2014
Impact of New Anticoagulants on the Blood Bank
Manufacturer: Daiichi Sankyo FDA Approval Date: 01/08/2015
New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.
The Definitive Thrombosis Update
Linda Wing, R.Ph. Risik Rask, Pharm.D.
The EINSTEIN DVT Study 'Xarelto' for the Acute and Continued Treatment of Symptomatic Deep Vein Thrombosis.
Atrial Fibrillation Warfarin and its newer alternatives
Care of the Anti-coagulated Trauma Patient Julie Mayglothling, MD, FACEP Emergencies in Medicine March 8 th, 2012.
  Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target
The case for switching to the emerging oral anticoagulants in Atrial Fibrillation Dr Neil Baldwin Consultant Physician & Clinical Lead for Stroke North.
Stop the Clot ™ David Henry and Tom Hogan Cardiovascular and Renal Drugs Advisory Committee U.S. Food and Drug Administration Adelphi,
Adam M. Levine, DO, FACC Clinical Assistant Professor of Medicine Rowan University September 12 th, 2015.
Dodson Thompson, DO Northlakes Community Clinic Minong, WI.
UK/CVS (1) | February 2013 Emerging technologies for stroke prevention in atrial fibrillation UK/CVS (1) | Date of preparation: February 2013.
Atrial Fibrillation Management Past, Present and Future
ALI R. RAHIMI, BOBBY WRIGHTS, MD, HOSSEIN AKHONDI, MD & CHRISTIAN M. RICHARD, MSC Clinical Correlation Between Effective Anticoagulants & Risk of Stroke:
ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.
A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.
Anticoagulation ACCP guidelines 2012
Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.
Anticoagulation Update
Novel Anticoagulants (NOACs) in Non Valvular Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Dalia Hawwass PGY2 June 2015.
N Engl J Med 2009;361: Stuart J. Connolly, M.D., Michael D. Ezekowitz, M.B., Ch.B., D.Phil., Salim Yusuf, F.R.C.P.C., D.Phil., John Eikelboom,
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D.,
Net clinical benefit of OAC
Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D., Daniel E. Singer, M.D., Werner Hacke, M.D., Ph.D., Gunter Breithardt,
Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated with Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
Blood/Blood Formation
Anticoagulants How much, which one & how long?
Anticoagulation: The Latest on Blood Thinners from Aspirin to Xarelto
Volume 149, Issue 6, Pages (June 2016)
Fadiea Al-Aieshy   PhD-student, MSc Pharm
You can never be too Thin…. An Update on NOACs
How Do We Incorporate Patient Perspectives Into Clinical Trial Design?
David R. Holmes, Jr., M.D. Mayo Clinic, Rochester
A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes
Efficacy and Safety of Dabigatran vs
Management of Direct Oral Anticoagulants
Ortho Warfarin Dosing Protocol
Anticoagulation in Atrial Fibrillation
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.
Aug, 2016.
Novel oral anticoagulants in comparison with warfarin
Click here for title Click here for subtitle
Reversal of Direct Oral Anticoagulants (DOAC)
Neurosurgery and DOACs
Which NOAC and When for Stroke Prevention in AF?
ACC 2003 Late Breaking Trials
Gianluigi Savarese et al. JCHF 2016;4:
Presentation transcript:

The New Oral Anticoagulants: Handle with Care Philip C. Comp, M.D., Ph.D. October 18, 2013

Speaker for dabigatran (Pradaxa®) and rivaroxaban (Xarelto®)

Anticoagulant Quiz Which commonly used anticoagulant does not require laboratory monitoring? Which anticoagulant has no antidote? The dose of which anticoagulant depends on renal function? ( Enoxaparin, Lovenox® )

Edoxaban

The New Oral Anticoagulants Dabigatran (Pradaxa®) Inhibits thrombin Twice a day Atrial fibrillation Apixaban (Eliquis®) Inhibits factor Xa Twice a day Atrial fibrillation Rivaroxaban (Xarelto®) Inhibits factor Xa Once a day Atrial fibrillation; DVT/PE treatment; Reduction in risk of DVT/PE (after 6 mn Tx); Hip/Knee prophylaxis;

Canine Model of Blood Coagulation Factor IX Factor X PROTHROMBIN

Canine Model of Blood Coagulation Effect of Warfarin Factor IXa Factor Xa THROMBIN

Canine Model of Blood Coagulation Oral Anti-Xa Factor IXa Factor Xa THROMBIN

Canine Model of Blood Coagulation Oral Anti-thrombin Factor IXa Factor Xa THROMBIN rivaroxaban apixaban

There is no free lunch The effectiveness of an anticoagulant must be weighed against the risk of bleeding Bleeding Thrombosis

Apixaban, Dabigatran and Rivaroxaban Oral Short half-lives Renal clearance No INRs No food interactions Few drug interactions

Prevention of Stroke-Apixaban Granger et al. NEJM 3654: , 2011Number needed to treat/1.8 years: 167

Atrial Fibrillation- Dabigatran Connolly et al. NEJM 361, % RRR ! Number needed to treat/ 2 years: 88

Atrial Fibrillation- Rivaroxaban C Patel et al. NEJM 365: , 2011 Number needed to treat/1.6 years: 135

Atrial Fibrillation- Dabigatran Modified from Connolly et al. NEJM 361, 2009 STROKE No Treatment Warfarin Dabigatran Number needed to treat NT 88 v. warfarin No Treatment CHADS 2 Scores % 2 35% % ESTIMATE 5% risk/year In a non-treated group

Percentage of AF patients with stroke per year No treatment 5.0% Warfarin 1.6% Dabigatran 1.0% ~ Modified from Connolly et al. NEJM 361, % 0.6% 68% of strokes gone; 32 occur 80% of strokes gone; 20 occur 100 strokes occur

STROKE = Ischemic Stroke and Hemorrhagic Stroke* * Subdural hematomas, epidural hematomas, subarachnoid hematomas and intracerebral hemorrhage

Stroke rates (percent/year) All Stroke Hemorrhagic Stroke Time INR in 2-3 range Dabigatran/ Warfarin 1.44/ / Rivaroxaban/ Warfarin (as treated) 2.61/ /0.755 Apixaban/ Warfarin 1.19/ /0.4762

Bleeding and death rates (percent/year) Major Bleeding Death Dabigatran/ Warfarin 3.11/ /4.13 Rivaroxaban/ Warfarin (as treated) 3.60/ /2.20 Apixaban/ Warfarin 2.13/ /3.94

Bleeding Event Rate (%/year) IntracranialGastrointestinal Apixaban Warfarin Dabigatran Warfarin Rivaroxaban Warfarin N Engl J Med 2011;365: N Engl J Med 2009;361: N Engl J Med 2011;365:

NNT with dabigatran for 1 year to prevent one adverse event compared to warfarin NNT Stroke or systemic embolus 172 Intracranial bleeding227 Major bleeding154 Life-threatening bleeding 286 Nature Reviews Cardiology 7, (January 2010)

Can atrial fibrillation studies be directly compared? Mean Age and CHADS 2 Score Apixaban 70y 2.1 ± 1.1 Rivaroxaban 73y 3.5 ± 0.94 Dabigatran 72y 2.1 ± 1.1 Direct comparison of strokes and bleeding between studies is difficult. CHF 1 Hypertension 1 Age > 75 1 Diabetes 1 Prior stroke 2

New oral agents in atrial fibrillation Apixaban superior to warfarin Rivaroxaban not inferior to warfarin Dabigatran superior to warfarin Davis, N Engl J Med 2012;366:

No food interactions Compare to WARFARIN AND FOOD

Dietitians

CHLOROPHOBIA (fear of the color green)

Green Tea

333 liters of green tea contain 1 mg vitamin K

Iceberg Lettuce

How do you test a new anticoagulant? Hip or knee joint replacement → Venogram Deep vein thrombosis → Prevent recurrence Atrial fibrillation → Prevent stroke $ $ $$$$$$$$

New anticoagulants have short half- lives (9-17 hours)

Forgetfulness 30% Other priorities 16% Decision to omit doses 11% Lack of information 9% Osterberg l et al. NEJM 353:

1,800,000 patients prescribed a statin: Patients filled prescriptions for a mean of 11.4 medications/3 month 10% of patients filled prescriptions for 23 or more medications. 10% had prescriptions written by 4 or more prescribers. Choudhry NK The Implications of Therapeutic Complexity on Adherence to Cardiovascular Medications. Archives of Internal Medicine 171: , 2011

Retrospective Study of Medication Prescription in Oklahoma City, n=3 64 year old man: 14 medications daily; 31 pills 61 year old woman: 15 medications; 39 pills 90 year old man: 15 medications; 27 pills

Drugs don’t work in patients who don’t take them C. Everett Koop, M.D

Typical Clinical Trial Patient

Who is the ideal patient? Does not like INRs Reliable Well insured

Who will have a bleed? Frail (<60 kg) Reduced creatinine clearance Over 80 years of age Harper. Bleeding Risk with Dabigatran in the Frail Elderly N Engl J Med 2012; 366:

Proper prescriber behavior At each visit – Are your taking drug X? At every visit – Why are you taking drug X? At each visit – Are you taking X every day?

KIDNEY FUNCTION IS IMPORTANT! CHECK THE CREATININE CLEARANCE

What is the effect of no more INRs? No more anticoagulation clinics and fewer office visits. Will that reduce compliance? BOUNCING BEN in a BAD candidate! INR

Who to switch from warfarin Not a cure for the bouncing INR Stroke risk: Least benefit to well controlled warfarin patients Fewer potential drug interactions in polypharmacy patients?

Warfarin > new anticoagulant Patients angst: Miss INRs Miss food restrictions

If bleeding occurs Little data available a. Factor VIIa b. Factor VIII Inhibitor Bypassing Activity (FEIBA) c. Hydration Fresh frozen plasma and Vitamin K are not the way to go!

Everyone is developing an antidote Oral anticoagulant inhibits factor Xa Xa Inhibitor

Everyone is developing an antidote A recombinant antidote (DU-176b) Xa

Surgery while on medication Dabigatran (100% renal) Rivaroxaban (65% renal clearance) Apixaban (25% renal clearance) When to stop the medication preoperatively depends on the medication and renal function. Look it up!

What is the cost per day* Dabigatran = $9.50 Rivaroxaban= $9.46 Apixaban = $9.40 *Sam's Club, Northwest Highway, OKC 10/10/13

Advising patients Explain they are taking lots of medications – stroke preventers critical Avoid friendly little black dogs and get someone else to clean the gutters!

Summary of New Anticoagulants Marginally better than warfarin for atrial fibrillation No food interactions; few drug interactions No need for INRs Short-half life – take regularly Check creatinine clearance yearly